Answer
Sugammadex, a modified gamma cyclodextrin and selective relaxant binding agent, forms complexes with rocuronium or vecuronium in plasma, reducing the amount available to bind nicotinic receptors at the neuromuscular junction and thereby reversing neuromuscular blockade.
Sources for this answer
- Sugammadex 100 mg/mL solution for injectionGlenmark Pharmaceuticals Europe Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 2Document updated
Sources checked